GSK plc vs iShares 10 20 Year Treasury Bond ETF — how do they compare? GSK plc trades at $50.37 (market cap $102.60B), while iShares 10 20 Year Treasury Bond ETF trades at $96.56. The key difference: GSK plc pays a 3.57% dividend while iShares 10 20 Year Treasury Bond ETF pays none, and GSK plc is trading nearer its 52-week high, iShares 10 20 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| GSK | TLH | |
|---|---|---|
Market Cap | $102.60B | — |
Sector | Health | Fixed Income |
52-Week High | $61.18 | $105.36 |
52-Week Low | $38.22 | $96.39 |
Enterprise Value | $123.04B | — |
Dividend Yield | 3.57% | — |
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
TLH trades at $96.57, up 0.19% today, with a bearish technical signal from moving averages and neutral oscillators. Recent dividends include $0.38 (July 2026), $0.36 (June 2026), and $0.41 (May 2026). Key financial ratios like P/E and ROE are unavailable, limiting fundamental clarity. Support and resistance cluster near $96-$97, indicating tight price consolidation amid weak momentum.
The outlook is cautious due to missing financial metrics and bearish technicals. Risks include reliance on dividend stability and macroeconomic pressures from rising yields. Opportunities may arise if fundamentals improve, but current data suggests limited upside without clearer earnings visibility or positive analyst sentiment.
Trailing returns across standard periods
Latest headlines on both assets
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →